Trial Description. Organizational Data. Secondary IDs

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "Trial Description. Organizational Data. Secondary IDs"

Transcription

1 Trial Description Title A randomized, double-blind, multicenter study to demonstrate equivalent efficacy and to compare safety and immunogenicity of a biosimilar etanercept (GP2015) and Enbrel in patients with moderate to severe chronic plaque-type psoriasis Trial Acronym EGALITY URL of the trial [---]* Brief Summary in Lay Language [---]* Brief Summary in Scientific Language [---]* Organizational Data DRKS-ID: DRKS Date of Registration in Partner Registry or other Primary Registry: 2013/07/04 Investigator Sponsored/Initiated Trial (IST/IIT): no Ethics Approval/Approval of the Ethics Committee: Approved (leading) Ethics Committee Nr.: A 125/13, Ethikkommission der Christian-Albrechts-Universität zu Kiel Secondary IDs EudraCT-No. (for studies acc. to Drug Law): Primary Registry-ID: NCT (Clinicaltrials.gov) Page 1 of 6

2 Health condition or Problem studied Free text: Chronic Plaque type psoriasis Interventions/Observational Groups Arm 1: GP2015 (Etanercept) Solution for s.c. injection in pre-filled syringe. The drug is administered in a dose of 50 mg twice weekly for the first 12 weeks and 50mg once weekly thereafter. The total duration of treatment can last up to 52 weeks. Arm 2: Enbrel (Etanercept) Solution for s.c. injection in pre-filled syringe. The drug is administered in a dose of 50 mg twice weekly for the first 12 weeks and 50mg once weekly thereafter. The total duration of treatment can last up to 52 weeks. Characteristics Study Type: Interventional Study Type Non-Interventional: [---]* Allocation: Randomized controlled trial Blinding: [---]* Who is blinded: patient/subject, investigator/therapist, assessor, data analyst Control: Active control (effective treament of control group) Purpose: Treatment Assignment: Parallel Phase: III Off-label use (Zulassungsüberschreitende Anwendung eines Arzneimittels): N/A Primary Outcome The primary efficacy variable is the PASI 75 response rate (proportion of patients showing at least a 75% improvement in PASI) after the first 12 weeks of treatment (Treatment Period 1). Secondary Outcome * PASI 50, 75 and 90 response rates * Time based response on PASI score * Clinical Safety and tolerability: assessment of vital signs, clinical laboratory variables, ECGs and Adverse Events monitoring * Injection Site Reactions * Immunogenicity: Measurement of rate of ADA (Anti-drug antibodies) formations against GP2015 and Enbrel. All secondary endpoints are assessed during the complete duration of the study until week 52. Page 2 of 6

3 Countries of recruitment BG Bulgaria DE EE Estonia CZ Czech Republic UA Ukraine UK United Kingdom RU Russian Federation HU Hungary PL Poland RO Romania ZA South Africa SK Slovakia Locations of Recruitment University Medical Center Lübeck University Medical Center Kiel Doctor's Practice Dresden Doctor's Practice Hamburg University Medical Center Köln Doctor's Practice Witten University Medical Center Mainz University Medical Center Münster University Medical Center Dresden Doctor's Practice München Medical Center Berlin Doctor's Practice Berlin Recruitment Planned/Actual: Actual (Anticipated or Actual) Date of First Enrollment: 2013/06/24 Target Sample Size: 546 Page 3 of 6

4 Planned/Actual: Actual (Anticipated or Actual) Date of First Enrollment: 2013/06/24 Target Sample Size: 546 Monocenter/Multicenter trial: Multicenter trial National/International: International Inclusion Criteria Gender: Both, male and female Minimum Age: 18 Years Maximum Age: no maximum age Additional Inclusion Criteria Chronic plaque-type psoriasis diagnosed for at least 6 months before baseline Moderate to severe psoriasis as defined at baseline by: PASI score of 10 or greater and, Investigator s Global Assessment score of 3 or greater (based on a scale of 0-4) and, Body Surface Area affected by plaque-type psoriasis of 10% or greater Chronic plaque-type psoriasis patients who have previously received phototherapy or systemic psoriasis therapy at least once or who are candidates for such therapies in the opinion of the investigator. Other Inclusion criteria may apply Exclusion criteria Forms of psoriasis other than chronic plaque-type Drug-induced psoriasis Ongoing use of prohibited treatments Previous exposure to etanercept Active ongoing inflammatory diseases other than psoriasis that might confound the evaluation of the benefit of treatment with etanercept Other exclusion criteria may apply Addresses Page 4 of 6

5 Primary Sponsor Hexal AG Industriestrasse Holzkirchen Telephone: [---]* [---]* Contact for Scientific Queries Universitätsklinikum Schleswig-Holstein, Campus Kiel Mr. Dr. Sascha Gerdes Schittenhelmstr Kiel Telephone: sgerdes at dermatology.uni-kiel.de Contact for Public Queries Universitaetsklinikum Schleswig-Holstein - Campus Kiel Mr. Dr. Sascha Gerdes Schittenhelmstrasse Kiel Telephone: sgerdes at dermatology.uni-kiel.de Sources of Monetary or Material Support Page 5 of 6

6 Commercial (pharmaceutical industry, medical engineering industry, etc.) Hexal AG Industriestrasse Holzkirchen Telephone: [---]* [---]* Status Recruitment Status: Recruiting complete, follow-up complete Study Closing (LPLV): 2015/03/30 Trial Publications, Results and other documents Paper [---]* * This entry means the parameter is not applicable or has not been set. Page 6 of 6

Feasibility study to evaluate the usability of the newly developed health care management software ecare*seniors in primary care practices.

Feasibility study to evaluate the usability of the newly developed health care management software ecare*seniors in primary care practices. Trial Description Title Patient-centered health care management in primary care: feasibility study evaluating the usability of the computer-based information system ecare*seniors for the individual health

More information

Trial Description. DRKS-ID: DRKS00006862 Date of Registration in DRKS: 2015/03/06 Date of Registration in Partner Registry: [---]*

Trial Description. DRKS-ID: DRKS00006862 Date of Registration in DRKS: 2015/03/06 Date of Registration in Partner Registry: [---]* PLEASE NOTE: This trial has been registered retrospectively. Trial Description Title Treatment with new oral anticoagulants in primary care practices Trial Acronym [---]* URL of the trial [---]* Brief

More information

Amendment 1 ( ): Extension of primary outcome measure (Acrophobia Questionnaire) by 6-month follow-up

Amendment 1 ( ): Extension of primary outcome measure (Acrophobia Questionnaire) by 6-month follow-up Trial Description Title Height anxiety study Trial Acronym [---]* URL of the trial [---]* Brief Summary in Lay Language The purpose of the study is to examine factors underlying exposure therapy in virtual

More information

Investigation of the effect of isomaltulose (PalatinoseTM) on metabolic parameters in subjects with Type 2 Diabetes.

Investigation of the effect of isomaltulose (PalatinoseTM) on metabolic parameters in subjects with Type 2 Diabetes. PLEASE NOTE: This trial has been registered retrospectively. Trial Description Title Investigation of the effect of isomaltulose (PalatinoseTM) on metabolic parameters in subjects with Type 2 Diabetes.

More information

Dopaminergic and cholinergic modulation of oculomotor control during saccades

Dopaminergic and cholinergic modulation of oculomotor control during saccades Trial Description Title Dopaminergic and cholinergic modulation of oculomotor control during saccades Trial Acronym URL of the trial Brief Summary in Lay Language In this basic science study we investigate

More information

Body measurements and body composition of pediatric patients with adiposity, type 2 or type 1 diabetes

Body measurements and body composition of pediatric patients with adiposity, type 2 or type 1 diabetes PLEASE NOTE: This trial has been registered retrospectively. Trial Description Title Body measurements and body composition of pediatric patients with adiposity, type 2 or type 1 diabetes Trial Acronym

More information

Impact of Anesthesia during endovascular treatment of acute ischemic stroke

Impact of Anesthesia during endovascular treatment of acute ischemic stroke Trial Description Title Impact of Anesthesia during endovascular treatment of acute ischemic stroke Trial Acronym STENOsIS URL of the trial [---]* Brief Summary in Lay Language In this study we will analyse

More information

Trial Description. Organizational Data. DRKS-ID: DRKS Date of Registration in DRKS: 2015/07/27. Title

Trial Description. Organizational Data. DRKS-ID: DRKS Date of Registration in DRKS: 2015/07/27. Title Trial Description Title PsYchoTHerapy - Intergenerational Actions Trial Acronym PYTHIA URL of the trial [---]* Brief Summary in Lay Language The DNA contains the genetic code, e.g. the genetic information.

More information

Trial Description. DRKS-ID: DRKS Date of Registration in DRKS: 2013/07/09. PLEASE NOTE: This trial has been registered retrospectively.

Trial Description. DRKS-ID: DRKS Date of Registration in DRKS: 2013/07/09. PLEASE NOTE: This trial has been registered retrospectively. PLEASE NOTE: This trial has been registered retrospectively. Trial Description Title Prospective, controlled study of deep brain stimulation (DBS) in the region of the posterior subthalamic area (PSA)

More information

The use of a three dimensional untrasound-based measurement device for the evaluation of subjects with and without neckpain

The use of a three dimensional untrasound-based measurement device for the evaluation of subjects with and without neckpain PLEASE NOTE: This trial has been registered retrospectively. Trial Description Title The use of a three dimensional untrasound-based measurement device for the evaluation of subjects with and without neckpain

More information

Evaluation of a patient's ressource srengthening psychotherapeutic intervention in treatment of residual depression symptoms

Evaluation of a patient's ressource srengthening psychotherapeutic intervention in treatment of residual depression symptoms PLEASE NOTE: This trial has been registered retrospectively. Trial Description Title Euthymic Therapy: a Randomised Controlled Trial Trial Acronym [---]* URL of the trial [---]* Brief Summary in Lay Language

More information

Trial Description. Organizational Data. DRKS-ID: DRKS Date of Registration in DRKS: 2015/01/30. Title. MiniMizer for Sleeve Optimization

Trial Description. Organizational Data. DRKS-ID: DRKS Date of Registration in DRKS: 2015/01/30. Title. MiniMizer for Sleeve Optimization Trial Description Title MiniMizer for Sleeve Optimization Trial Acronym MISO URL of the trial [---]* Brief Summary in Lay Language There are different methods of surgical treatment for obese persons. Sleeve

More information

Trial Description. Organizational Data. Secondary IDs. Health condition or Problem studied

Trial Description. Organizational Data. Secondary IDs. Health condition or Problem studied Trial Description Title Microsurgical versus minimal invasive approach (Metrix instrument), for lumbar disc herniation surgery: a randomized controlled trial on clinical outcome. Trial Acronym MMILD URL

More information

Raman spectroscopy: Setup of an experimental system for analysis of urinary stone composition

Raman spectroscopy: Setup of an experimental system for analysis of urinary stone composition PLEASE NOTE: This trial has been registered retrospectively. Trial Description Title Raman spectroscopy: Setup of an experimental system for analysis of urinary stone composition Trial Acronym Ramalith

More information

Trial Description. Organizational Data. DRKS-ID: DRKS Date of Registration in DRKS: 2014/02/19

Trial Description. Organizational Data. DRKS-ID: DRKS Date of Registration in DRKS: 2014/02/19 PLEASE NOTE: This trial has been registered retrospectively. Trial Description Title Neuroendocrine and psychophysiological effects of the sentinel lymph node excision in melanoma patients under local

More information

WAKE-Up Pilot Study, Mental Training for patients with relapse-remitting multiple sclerosis and fatigue

WAKE-Up Pilot Study, Mental Training for patients with relapse-remitting multiple sclerosis and fatigue PLEASE NOTE: This trial has been registered retrospectively. Trial Description Title WAKE-Up Pilot Study, Mental Training for patients with relapse-remitting multiple sclerosis and fatigue Trial Acronym

More information

Work-related diseases of occupational therapists - pilot study for creating an "occupational therapist-cohort" in Germany

Work-related diseases of occupational therapists - pilot study for creating an occupational therapist-cohort in Germany Trial Description Title Work-related diseases of occupational therapists - pilot study for creating an "occupational therapist-cohort" in Trial Acronym ERGO-Study URL of the trial [---]* Brief Summary

More information

In this observational study, the effect of dabigatran and rivaroxaban on platelets will be evaluated.

In this observational study, the effect of dabigatran and rivaroxaban on platelets will be evaluated. Trial Description Title Effect of dabigatran and rivaroxaban on Platelets Trial Acronym BIG-ROX-P URL of the trial [---]* Brief Summary in Lay Language In this observational study, the effect of dabigatran

More information

Evatuation of long-term biomechanical effects of an elastic knee sleeve in subjects with moderate to severe medial knee osteoarthritis

Evatuation of long-term biomechanical effects of an elastic knee sleeve in subjects with moderate to severe medial knee osteoarthritis Trial Description Title Evatuation of long-term biomechanical effects of an elastic knee sleeve in subjects with moderate to severe medial knee osteoarthritis Trial Acronym [---]* URL of the trial [---]*

More information

PLEASE NOTE: This study has been imported from ClinicalTrials.gov without additional data checks.

PLEASE NOTE: This study has been imported from ClinicalTrials.gov without additional data checks. PLEASE NOTE: This study has been imported from ClinicalTrials.gov without additional data checks. Trial Description Title A Phase IIIb, Multicentre, Open-label Study of Nilotinib in Adult Patients With

More information

"Smart insole for patients with diabetic neuropathy for the prevention of foot ulcers"

Smart insole for patients with diabetic neuropathy for the prevention of foot ulcers Trial Description Title "Smart insole for patients with diabetic neuropathy for the prevention of foot ulcers" Trial Acronym Insole URL of the trial [---]* Brief Summary in Lay Language In patients with

More information

Acute influence of a nutritional ergogenic aid on endurance performance a placebo controlled double blind trial

Acute influence of a nutritional ergogenic aid on endurance performance a placebo controlled double blind trial Trial Description Title Acute influence of a nutritional ergogenic aid on endurance performance a placebo controlled double blind trial Trial Acronym NEP URL of the trial [---]* Brief Summary in Lay Language

More information

Prospective multicenter study for functional evaluation of transoral laser microsurgery (TLM) for supraglottic carcinomas - SUPRATOL

Prospective multicenter study for functional evaluation of transoral laser microsurgery (TLM) for supraglottic carcinomas - SUPRATOL Trial Description Title Prospective multicenter study for functional evaluation of transoral laser microsurgery (TLM) for supraglottic carcinomas - SUPRATOL Trial Acronym SUPRATOL URL of the trial [---]*

More information

A Phase 2 Study of Interferon Beta-1a (Avonex ) in Ulcerative Colitis

A Phase 2 Study of Interferon Beta-1a (Avonex ) in Ulcerative Colitis A Phase 2 Study of (Avonex ) in Ulcerative Colitis - Study Results - ClinicalTrials.gov A Phase 2 Study of (Avonex ) in Ulcerative Colitis This study has been completed. Sponsor: Biogen Idec Information

More information

Trial Description. DRKS-ID: DRKS00006819 Date of Registration in DRKS: 2014/10/31 Date of Registration in Partner Registry: [---]* Title

Trial Description. DRKS-ID: DRKS00006819 Date of Registration in DRKS: 2014/10/31 Date of Registration in Partner Registry: [---]* Title Trial Description Title SCHILD - protective intervention for longtime course in depression Trial Acronym SCHILD URL of the trial [---]* Brief Summary in Lay Language Even if depression is treated appropriate

More information

Sponsor Novartis. Generic Drug Name Secukinumab. Therapeutic Area of Trial Psoriasis. Approved Indication investigational

Sponsor Novartis. Generic Drug Name Secukinumab. Therapeutic Area of Trial Psoriasis. Approved Indication investigational Clinical Trial Results Database Page 2 Sponsor Novartis Generic Drug Name Secukinumab Therapeutic Area of Trial Psoriasis Approved Indication investigational Clinical Trial Results Database Page 3 Study

More information

Changes in liver volume as determined by MRI scans after two weeks of a low energy diet (t0: before start of the diet; t1: after two weeks of diet)

Changes in liver volume as determined by MRI scans after two weeks of a low energy diet (t0: before start of the diet; t1: after two weeks of diet) Trial Description Title Influence of different preoperative low energy diets on changes in liver volume, liver fat content, visceral fat and body composition as well as liver and adipose tissue mrna expression

More information

How to Design a Clinical Trial. Harvey Lui, MD, FRCPC

How to Design a Clinical Trial. Harvey Lui, MD, FRCPC How to Design a Clinical Trial Harvey Lui, MD, FRCPC Outline Why do clinical trials? How to review a study protocol How to design a study protocol Why do a clinical trial? Why do a clinicaltrial? To answer

More information

Description of Commitment

Description of Commitment U.S. Postmarketing s Table: Name of Product ANDROGEL (testosterone) CREON (pancrelipase) CREON (pancrelipase) DEPAKOTE (divalproex sodium) NDA/ NDA 22309 NDA 20725 NDA 20725 NDA 22267 125057/0 125057/89

More information

Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE - Obesity and Prediabetes

Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE - Obesity and Prediabetes Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE - Obesity and Prediabetes This trial is conducted in Africa, Asia, Europe, Oceania,

More information

Efficacy, safety and preference study of a insulin pen PDS290 vs. a Novo Nordisk marketed insulin pen in diabetics

Efficacy, safety and preference study of a insulin pen PDS290 vs. a Novo Nordisk marketed insulin pen in diabetics Efficacy, safety and preference study of a insulin pen PDS290 vs. a Novo Nordisk marketed insulin pen in diabetics This trial is conducted in the United States of America (USA). The aim of this clinical

More information

The Clinical Trial Protocol Guide. BioStrategics Consulting Ltd.

The Clinical Trial Protocol Guide. BioStrategics Consulting Ltd. The Clinical Trial Protocol Guide 2011 BioStrategics Consulting Ltd. BioStrategics Consulting Ltd THE CLINICAL TRIAL PROTOCOL The clinical trial protocol to test one s product, to confirm or reject a specific

More information

Effect of liraglutide on body weight in overweight or obese subjects with type 2 diabetes: SCALE - Diabetes

Effect of liraglutide on body weight in overweight or obese subjects with type 2 diabetes: SCALE - Diabetes Effect of liraglutide on body weight in overweight or obese subjects with type 2 diabetes: SCALE - Diabetes This trial is conducted in Africa, Asia, Europe and the United States of America (USA). The aim

More information

If several different trials are mentioned in one publication, the data of each should be extracted in a separate data extraction form.

If several different trials are mentioned in one publication, the data of each should be extracted in a separate data extraction form. General Remarks This template of a data extraction form is intended to help you to start developing your own data extraction form, it certainly has to be adapted to your specific question. Delete unnecessary

More information

Methods for Measuring Dose Escalation in TNF Antagonists for Rheumatoid Arthritis Patients Treated in Routine Clinical Practice

Methods for Measuring Dose Escalation in TNF Antagonists for Rheumatoid Arthritis Patients Treated in Routine Clinical Practice Methods for Measuring Dose Escalation in TNF Antagonists for Rheumatoid Arthritis Patients Treated in Routine Clinical Practice Gu NY 1, Huang XY 2, Globe D 2, Fox KM 3 1 University of Southern California,

More information

FH Studies Collaboration Lecturers at the European Society of Atherosclerosis Congress 2015. Pre- and Post- Event Questionnaires

FH Studies Collaboration Lecturers at the European Society of Atherosclerosis Congress 2015. Pre- and Post- Event Questionnaires FH Studies Collaboration Lecturers at the European Society of Atherosclerosis Congress 2015 Pre- and Post- Event Questionnaires The information on these slides is intended for educational purposes only.

More information

REF/2011/03/002226 CTRI Website URL - http://ctri.nic.in

REF/2011/03/002226 CTRI Website URL - http://ctri.nic.in Clinical Trial Details (PDF Generation Date :- Thu, 14 Jul 2016 15:20:58 GMT) CTRI Number Last Modified On 28/01/2014 Post Graduate Thesis Type of Trial Type of Study Study Design Public Title of Study

More information

Brief Communications. Awad Mohamed Ahmed, MD. Abstract

Brief Communications. Awad Mohamed Ahmed, MD. Abstract Awad Mohamed Ahmed, MD Professor of Medicine, University of Bahr Elghazal, Khartoum, Sudan For correspondence Professor Awad Mohamed Ahmed E-mail: awad.sd@gmail.com Tel.: +249 912344936 Abstract Randomized

More information

SYNOPSIS. Risperidone: Clinical Study Report CR003274

SYNOPSIS. Risperidone: Clinical Study Report CR003274 SYNOPSIS Protocol No: CR003274 Title of Study: An Open-Label, Long-Term Trial of Risperidone Long-Acting Microspheres in the Treatment of Subjects Diagnosed with Schizophrenia Coordinating Investigator:

More information

Version History. Previous Versions. Policy Title. Drugs for MS.Drug facts box Glatiramer Acetate Version 1.0 Author

Version History. Previous Versions. Policy Title. Drugs for MS.Drug facts box Glatiramer Acetate Version 1.0 Author Version History Policy Title Drugs for MS.Drug facts box Glatiramer Acetate Version 1.0 Author West Midlands Commissioning Support Unit Publication Date Jan 2013 Review Date Supersedes/New (Further fields

More information

Active centers: 2. Number of patients/subjects: Planned: 20 Randomized: Treated: 20 Evaluated: Efficacy: 13 Safety: 20

Active centers: 2. Number of patients/subjects: Planned: 20 Randomized: Treated: 20 Evaluated: Efficacy: 13 Safety: 20 These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinialTrials.gov

More information

Journal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators

Journal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators Journal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators Shaikha Al Naimi Doctor of Pharmacy Student College of Pharmacy Qatar University

More information

Clinical Trials Glossary

Clinical Trials Glossary Clinical Trials Glossary ADME: an acronym for absorption, distribution, metabolism and elimination. ADME studies determine how a drug is absorbed by the body, the chemical changes that it may undergo and

More information

Synopsis. Adalimumab M Abbreviated Clinical Study Report R&D/08/1036. (For National Authority Use Only) to Part of Dossier: Volume:

Synopsis. Adalimumab M Abbreviated Clinical Study Report R&D/08/1036. (For National Authority Use Only) to Part of Dossier: Volume: Synopsis Abbott Laboratories Name of Study Drug: Adalimumab Name of Active Ingredient: Adalimumab Title of Study: Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This file is posted on the Bayer HealthCare Clinical Trials Registry and Results website. It is provided for patients and healthcare professionals to increase the transparency of

More information

Patient Input Information Clinical Trials Outcomes Common Drug Review

Patient Input Information Clinical Trials Outcomes Common Drug Review CDEC FINAL RECOMMENDATION USTEKINUMAB (Stelara Janssen Inc.) Indication: Psoriatic Arthritis Recommendation: The Canadian Drug Expert Committee (CDEC) recommends that ustekinumab not be listed at the submitted

More information

Riociguat Clinical Trial Program

Riociguat Clinical Trial Program Riociguat Clinical Trial Program Riociguat (BAY 63-2521) is an oral agent being investigated as a new approach to treat chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension

More information

Biostat Methods STAT 5820/6910 Handout #6: Intro. to Clinical Trials (Matthews text)

Biostat Methods STAT 5820/6910 Handout #6: Intro. to Clinical Trials (Matthews text) Biostat Methods STAT 5820/6910 Handout #6: Intro. to Clinical Trials (Matthews text) Key features of RCT (randomized controlled trial) One group (treatment) receives its treatment at the same time another

More information

Joint Position on the Disclosure of Clinical Trial Information via Clinical Trial Registries and Databases 1 Updated November 10, 2009

Joint Position on the Disclosure of Clinical Trial Information via Clinical Trial Registries and Databases 1 Updated November 10, 2009 Joint Position on the Disclosure of Clinical Trial Information via Clinical Trial Registries and Databases 1 Updated November 10, 2009 The innovative pharmaceutical industry 2 is committed to the transparency

More information

NCT00272090. sanofi-aventis HOE901_3507. insulin glargine

NCT00272090. sanofi-aventis HOE901_3507. insulin glargine These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: Generic drug name:

More information

Research Study Protocol Template

Research Study Protocol Template Research Study Protocol Template (For clinical trials) Instructions This protocol template is a tool to facilitate the development of a research study protocol specifically designed for the investigator

More information

CAN-FITE BIOPHARMA LTD.

CAN-FITE BIOPHARMA LTD. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace

More information

REF/2011/08/ CTRI Website URL -

REF/2011/08/ CTRI Website URL - Clinical Trial Details (PDF Generation Date :- Sat, 23 Jul 2016 17:36:46 GMT) CTRI Number Last Modified On 21/02/2013 Post Graduate Thesis Type of Trial Type of Study Study Design Public Title of Study

More information

European Research Council

European Research Council ERC Starting Grant Outcome: Indicative statistics Reproduction is authorised provided the source ERC is acknowledged ERCEA/JH. ERC Starting Grant: call Submitted and selected proposals by domain Submitted

More information

European Research Council

European Research Council ERC Advanced Grants 2011 Outcome: Indicative Statistics Reproduction is authorised provided that the source ERC is acknowledged NB: In these graphs grantee refers to a candidate selected for ERC funding

More information

FACT SHEET (Available at http://prsinfo.clinicaltrials.gov/) Registration at ClinicalTrials.gov: As required by Public Law 110-85, Title VIII

FACT SHEET (Available at http://prsinfo.clinicaltrials.gov/) Registration at ClinicalTrials.gov: As required by Public Law 110-85, Title VIII 10/27/09 NOTE: Section 2, Timing of Registration at ClinicalTrials.gov, was revised on 10/23/09. This document supersedes the Fact Sheet issued on 11/09/07. Note that the new text is highlighted below.

More information

Clinical Trial Results Database Page 1

Clinical Trial Results Database Page 1 Clinical Trial Results Database Page 1 Sponsor Novartis Generic Drug Name SBR759 Therapeutic Area of Trial Chronic kidney disease (CKD) Approved Indication Investigational Study Number CSBR759A2201 (12-month

More information

European Research Council

European Research Council ERC Advanced Grants 213 Outcome: Indicative statistics Reproduction is authorised provided the source ERC is acknowledged NB: In these graphs, grantee refers to a candidate selected for ERC funding. Country

More information

Homma A, Imai Y, Tago H, Asada T, et al. Dement Geriatr Cogn Disord. 2009;27(3):232-9. Epub 2009 Feb 25.

Homma A, Imai Y, Tago H, Asada T, et al. Dement Geriatr Cogn Disord. 2009;27(3):232-9. Epub 2009 Feb 25. ALZIL (Donepezil) Available as tablets: 5 mg, 10 mg (1) Indications (for elderly): symptomatic treatment of patients with mild, moderate and severe dementia of the Alzheimer s type (2) Recent trials: Abstract

More information

Is Monotherapy Treatment of Etanercept Effective Against Plaque Psoriasis?

Is Monotherapy Treatment of Etanercept Effective Against Plaque Psoriasis? Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2011 Is Monotherapy Treatment of Etanercept

More information

Critical appraisal form

Critical appraisal form Assessing scientific admissibility and merit of published articles Critical appraisal form Section A: Reference of Article Author(s) and Affiliation(s): Title of Article: Journal: Volume and Page Numbers:

More information

FREEDOM C: A 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Comparison of the Efficacy and Safety of Oral UT-15C

FREEDOM C: A 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Comparison of the Efficacy and Safety of Oral UT-15C FREEDOM C: A 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Comparison of the Efficacy and Safety of Oral UT-15C SR in Combination with an ERA and/or a PDE-5 Inhibitor

More information

Avastin in Metastatic Breast Cancer

Avastin in Metastatic Breast Cancer Non-interventional study Avastin in Metastatic Breast Cancer ML 21165 / 2007 Clinical Study Report Synopsis ROCHE ML21165 / WiSP Project RH09 / V. 1.0 / 24.06.2013 ROCHE ML21165-2 - Name of Sponsor Roche

More information

Clinical Study Report Synopsis. A psoriasis plaque test trial with LP0113 spray in patients with psoriasis vulgaris

Clinical Study Report Synopsis. A psoriasis plaque test trial with LP0113 spray in patients with psoriasis vulgaris This document has been downloaded from \VW'\V.leo-pharma.com subject to the terms of use state on the website. It contains data and results regarding approved and non-approved uses, formulations or treatment

More information

ANWICU knowledge

ANWICU knowledge ANWICU knowledge www.anwicu.org.uk This presenta=on is provided by ANWICU We are a collabora=ve associa=on of ICUs in the North West of England. Permission to provide this presenta=on has been granted

More information

Advancing research: a physician s guide to clinical trials

Advancing research: a physician s guide to clinical trials Advancing research: a physician s guide to clinical trials Recruiting and retaining trial participants is one of the greatest obstacles to developing the next generation of Alzheimer s treatments Alzheimer

More information

The Correlation Between Blood omega3 and ADHD

The Correlation Between Blood omega3 and ADHD The Correlation Between Blood omega3 and ADHD This study is not yet open for participant recruitment. (see Contacts and Locations) Verified March 2015 by Ziv Hospital Sponsor: Ayelet Omer Armon Information

More information

Subject: No. Page PROTOCOL AND CASE REPORT FORM DEVELOPMENT AND REVIEW Standard Operating Procedure

Subject: No. Page PROTOCOL AND CASE REPORT FORM DEVELOPMENT AND REVIEW Standard Operating Procedure 703 1 of 11 POLICY The Beaumont Research Coordinating Center (BRCC) will provide advice to clinical trial investigators on protocol development, content and format. Upon request, the BRCC will review a

More information

Biotie Therapies Oyj Biotie Therapies Corp. Varsinainen yhtiökokous 26.5.2015 Annual General Meeting 26 May 2015

Biotie Therapies Oyj Biotie Therapies Corp. Varsinainen yhtiökokous 26.5.2015 Annual General Meeting 26 May 2015 Biotie Therapies Oyj Biotie Therapies Corp. Varsinainen yhtiökokous 26.5.2015 Annual General Meeting 26 May 2015 1 Timo Veromaa President & CEO 2 Company Highlights 2014 through Q1 2015 Continued advances

More information

The summary table below shows how the composition of the trading partner groups changes on 1 January 2015 as a result of the enlargement.

The summary table below shows how the composition of the trading partner groups changes on 1 January 2015 as a result of the enlargement. 1 Update of trade weights underlying effective exchange rates and harmonised competitiveness indicators as Lithuania joins the euro area on 1 January 2015 The trade weights underlying the calculation of

More information

The European Research Council awards its first grants

The European Research Council awards its first grants MEMO/07/586 Brussels, 14 December 2007 The European Research Council awards its first grants The ERC is a major innovation within the European research system, and is established under the European Union

More information

INTRODUCTION TO CLINICAL TRIAL. Dr.K.T. Manisenthil Kumar, Head, Department of pharmacology, KMCH college of pharmacy, Coimbatore, Tamilnadu, India.

INTRODUCTION TO CLINICAL TRIAL. Dr.K.T. Manisenthil Kumar, Head, Department of pharmacology, KMCH college of pharmacy, Coimbatore, Tamilnadu, India. INTRODUCTION TO CLINICAL TRIAL Dr.K.T. Manisenthil Kumar, Head, Department of pharmacology, KMCH college of pharmacy, Coimbatore, Tamilnadu, India. INTRODUCTION The safety and toxicity data generated from

More information

Version History. Previous Versions. for secondary progressive MS (SPMS) Policy Title. Drugs for MS.Drug facts box Interferon beta 1b

Version History. Previous Versions. for secondary progressive MS (SPMS) Policy Title. Drugs for MS.Drug facts box Interferon beta 1b Version History Policy Title Drugs for MS.Drug facts box Interferon beta 1b for secondary progressive MS (SPMS) Version 1.0 Author West Midlands Commissioning Support Unit Publication Date Jan 2013 Review

More information

2. Background The combined presentation of calcipotriol and betamethasone dipropionate had not previously been considered by the PBAC.

2. Background The combined presentation of calcipotriol and betamethasone dipropionate had not previously been considered by the PBAC. PUBLIC SUMMARY DOCUMENT Product: Calcipotriol with betamethasone dipropionate, ointment, 50 micrograms- 500 micrograms (base) per g, Daivobet Sponsor: CSL Biotherapies Limited Date of PBAC Consideration:

More information

CLINICAL RESEARCH PROTOCOL CHECKLIST

CLINICAL RESEARCH PROTOCOL CHECKLIST CLINICAL RESEARCH PROTOCOL CHECKLIST [taken from ICH GCP : Guidance for Industry, Good Clinical Practice: Consolidated Guidance, Revision 1 (R1) June 1996] ICH GCP, Section 6. CLINICAL TRIAL PROTOCOL AND

More information

ustekinumab 45mg solution for injection in pre-filled syringe (Stelara ) SMC No. (944/14) Janssen-Cilag Ltd

ustekinumab 45mg solution for injection in pre-filled syringe (Stelara ) SMC No. (944/14) Janssen-Cilag Ltd ustekinumab 45mg solution for injection in pre-filled syringe (Stelara ) SMC No. (944/14) Janssen-Cilag Ltd 07 February 2014 The Scottish Medicines Consortium (SMC) has completed its assessment of the

More information

Samer El Rayess, M.D. Internal Medicine, PGY3 29 January 2016

Samer El Rayess, M.D. Internal Medicine, PGY3 29 January 2016 Samer El Rayess, M.D. Internal Medicine, PGY3 29 January 2016 Case Scenario Mr. X., a 50 year old man heavy smoker 80 pack / year known to have -COPD on spiriva at home last exacerbation 9 months ago -Hypertension

More information

2.0 Synopsis. Vicodin CR (ABT-712) M05-765 Clinical Study Report R&D/07/095. (For National Authority Use Only) to Part of Dossier: Volume:

2.0 Synopsis. Vicodin CR (ABT-712) M05-765 Clinical Study Report R&D/07/095. (For National Authority Use Only) to Part of Dossier: Volume: 2.0 Synopsis Abbott Laboratories Name of Study Drug: Vicodin CR Name of Active Ingredient: Hydrocodone/Acetaminophen Extended Release (ABT-712) Individual Study Table Referring to Part of Dossier: Volume:

More information

A Study To Evaluate PF With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

A Study To Evaluate PF With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome A service of the U.S. National Institutes of Health Trial record 1 of 5 for: efficacy of PF-04449913 Previous Study Return to List Next Study A Study To Evaluate PF-04449913 With Chemotherapy In Patients

More information

UCB. Certolizumab pegol (CIMZIA ) for the treatment of Rheumatoid Arthritis PATIENT ACCESS SCHEME (PAS) SUBMISSION TO NICE

UCB. Certolizumab pegol (CIMZIA ) for the treatment of Rheumatoid Arthritis PATIENT ACCESS SCHEME (PAS) SUBMISSION TO NICE UCB Certolizumab pegol (CIMZIA ) for the treatment of Rheumatoid Arthritis PATIENT ACCESS SCHEME (PAS) SUBMISSION TO NICE July 23 d 2009 1 Executive summary UCB have proposed a patient access scheme (PAS)

More information

Clinical Study Report Synopsis

Clinical Study Report Synopsis Clinical Study Report Synopsis A Phase 1, Multi-Centre, Randomised, Vehicle-Controlled, Double-Blinded, Explorative Clinical Trial to Evaluate a Left-Right Design in Adults with Mild to Moderate Atopic

More information

påçííáëü=jéçáåáåéë=`çåëçêíáìã==

påçííáëü=jéçáåáåéë=`çåëçêíáìã== påçííáëü=jéçáåáåéë=`çåëçêíáìã== adalimumab 40mg pre-filled syringe for subcutaneous injection (Humira ) No. (218/05) Abbott New indication: treatment of active and progressive psoriatic arthritis in adults

More information

Joint Research Centre (JRC) Economic Analysis of Electronic Identification (EID) of Small Ruminants in Member States

Joint Research Centre (JRC) Economic Analysis of Electronic Identification (EID) of Small Ruminants in Member States 1 Joint Research Centre (JRC) Economic Analysis of Electronic Identification (EID) of Small Ruminants in Member States IPSC - Institute for the Protection and Security of the Citizen Ispra - Italy http://ipsc.jrc.ec.europa.eu/

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace

More information

THE ORGANISATION AND FINANCING OF HEALTH CARE SYSTEM IN LATVIA

THE ORGANISATION AND FINANCING OF HEALTH CARE SYSTEM IN LATVIA THE ORGANISATION AND FINANCING OF HEALTH CARE SYSTEM IN LATVIA Eriks Mikitis Ministry of Health of the Republic of Latvia Department of Health Care Director General facts, financial resources Ministry

More information

Novel Trial Designs in T2D to Satisfy Regulatory Requirements for CV Safety

Novel Trial Designs in T2D to Satisfy Regulatory Requirements for CV Safety Novel Trial Designs in T2D to Satisfy Regulatory Requirements for CV Safety Anders Svensson MD, PhD Head of Global Clinical Development Metabolism, F Hoffmann LaRoche Ltd. Basel, Switzerland Overview of

More information

Template for essential information to be provided for proposals including clinical trials / studies / investigations

Template for essential information to be provided for proposals including clinical trials / studies / investigations Template for essential information to be provided for proposals including clinical trials / studies / investigations Document history Version 2016callsV1 September 2015 Modifications (compared to previous

More information

SURVEY ON THE TRAINING OF GENERAL CARE NURSES IN THE EUROPEAN UNION. The current minimum training requirements for general care nurses

SURVEY ON THE TRAINING OF GENERAL CARE NURSES IN THE EUROPEAN UNION. The current minimum training requirements for general care nurses SURVEY ON THE TRAINING OF GENERAL CARE NURSES IN THE EUROPEAN UNION This survey serves as a background document for the discussion of the Commission's legislative proposal to modernize the minimum requirements

More information

Humulin (LY041001) Page 1 of 1

Humulin (LY041001) Page 1 of 1 (LY041001) These clinical study results are supplied for informational purposes only in the interests of scientific disclosure. They are not intended to substitute for the FDA-approved package insert or

More information

February 2012 compared with January 2012 Volume of retail trade down by 0.1% in euro area Down by 0.4% in EU27

February 2012 compared with January 2012 Volume of retail trade down by 0.1% in euro area Down by 0.4% in EU27 54/2012-4 April 2012 February 2012 compared with January 2012 Volume of retail trade down by 0.1% in euro area Down by 0.4% in EU27 In February 2012 compared with January 2012, the volume of retail trade

More information

CLINICAL INVESTIGATION OF MEDICAL DEVICES FOR HUMAN

CLINICAL INVESTIGATION OF MEDICAL DEVICES FOR HUMAN Document CEN TC 258/WG2 N15 (Draft # 6, June 2000) CEN TC 258 Committee Enquiry/ISO TC 194 Committee Draft EN ISO 14155 CLINICAL INVESTIGATION OF MEDICAL DEVICES FOR HUMAN SUBJECTS PART 2: CLINICAL INVESTIGATION

More information

Strategic Initiatives Retail Banking

Strategic Initiatives Retail Banking Strategic Initiatives Retail Banking Branch Sales Force Effectiveness Fund Management Market Growth Funds A Global Comparison Assets Under Management In bn Regional/Country Growth Rates 2004 2005 +6% AUM

More information

Sponsor Novartis Pharmaceuticals

Sponsor Novartis Pharmaceuticals Clinical Trial Results Database Page 1 Sponsor Novartis Pharmaceuticals Generic Drug Name Indacaterol Therapeutic Area of Trial Chronic Obstructive Pulmonary Disease (COPD) Indication studied: COPD Study

More information

ENTERING THE EU BORDERS & VISAS THE SCHENGEN AREA OF FREE MOVEMENT. EU Schengen States. Non-Schengen EU States. Non-EU Schengen States.

ENTERING THE EU BORDERS & VISAS THE SCHENGEN AREA OF FREE MOVEMENT. EU Schengen States. Non-Schengen EU States. Non-EU Schengen States. ENTERING THE EU BORDERS & VISAS THE SCHENGEN AREA OF FREE MOVEMENT An area without internal borders where EU citizens and non-eu nationals may move freely EU Schengen States Non-Schengen EU States IS Azores

More information

A Guide to Clinical Trials

A Guide to Clinical Trials A Guide to Clinical Trials For young people with cancer and their parents Children s Cancer and Leukaemia Group www.cclg.org.uk Original booklet produced in conjunction with the CCLG Patient Advocacy Committee.

More information

Statistical Analysis Plan and Clinical Study Report

Statistical Analysis Plan and Clinical Study Report Statistical Analysis Plan and Clinical Study Report Zibao Zhang ( 张子豹 ), PhD Associate Director, Biostatistics PPD China Presented at the 2nd Clinical Data Management Training September 2010, SMMU, Shanghai

More information

1 of 6 6/1/13 6:49 PM

1 of 6 6/1/13 6:49 PM A service of the U.S. National Institutes of Health Trial record 7 of 203 for: Melanoma Analysis Previous Study Return to List Next Study Expression Analysis of Specific Markers in Non-small Cell Lung

More information

MEDICINES CONTROL COUNCIL

MEDICINES CONTROL COUNCIL MEDICINES CONTROL COUNCIL SECTION 21 APPLICATION COUNCIL'S RESPONSIBILITIES AND LIABILITY WHEN PERFORMING ITS FUNCTION IN TERMS OF SECTION 21 OF ACT 101 OF 1965 In terms of this Section the Authority/Council

More information

Update of trade weights data underlying the EERs and HCIs: extending the group of 20 trading partners to include Croatia from 1 July 2013

Update of trade weights data underlying the EERs and HCIs: extending the group of 20 trading partners to include Croatia from 1 July 2013 1 Update of trade weights data underlying the EERs and HCIs: extending the group of 20 trading partners to include Croatia from 1 July 2013 The trade weights underlying the calculation of the effective

More information